The Landmark MoU Between DNDi and Dubai Health

In a significant step for global health research, the Drugs for Neglected Diseases initiative (DNDi) and Dubai Health have formalized a Memorandum of Understanding (MoU) to propel research and training efforts against neglected diseases. Signed on February 10, 2026, at the World Health Expo Dubai (WHX), this partnership marks DNDi's first formal collaboration in the Middle East. Dr. Hanan Al Suwaidi, Deputy CEO and Chief Academic Officer of Dubai Health as well as Provost of Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), and Dr. Luis Pizarro, Executive Director of DNDi, affixed their signatures in the presence of dignitaries including the French Ambassador to the UAE.

This agreement establishes a robust framework for joint endeavors in medical education, cutting-edge research, and hands-on clinical training. It aligns perfectly with the UAE's vision to become a global hub for healthcare innovation, leveraging Dubai's integrated academic health system to address pressing global health inequities. Researchers and students in the UAE now have unprecedented access to DNDi's expertise in needs-driven drug development.

What Are Neglected Diseases and Why Do They Matter?

Neglected tropical diseases (NTDs), also known as neglected diseases, encompass a group of infectious conditions primarily affecting impoverished communities in tropical and subtropical regions. These include parasites, bacteria, viruses, and fungi that cause debilitating illnesses like sleeping sickness (human African trypanosomiasis), Chagas disease, leishmaniasis (both cutaneous and visceral forms), mycetoma, dengue, and others. Globally, over one billion people suffer from NTDs, leading to chronic disability, stigma, and economic loss estimated in billions annually.

In the Middle East and North Africa (MENA) region, NTDs such as cutaneous leishmaniasis remain endemic, with historical data showing millions affected by hookworm, fascioliasis, and trachoma. Though less prevalent in affluent UAE, the proximity to endemic zones and migration flows underscore the need for preparedness. Climate change exacerbates vector-borne diseases like dengue, making regional research vital. This partnership positions UAE academics at the forefront of combating these 'diseases of poverty' through innovative research outputs.

DNDi's Proven Impact in Drug Development

Founded in 2003 as a not-for-profit research and development (R&D) organization, DNDi has revolutionized treatment for neglected patients. Partnering with over 130 public and private entities, it has delivered 13 affordable treatments for six deadly diseases since inception, with a portfolio exceeding 40 projects including 20+ new chemical entities.

• Fexinidazole: First all-oral treatment for sleeping sickness, replacing toxic injections and treating both forms.
• Pediatric formulations for Chagas disease: Lifesaving for children, addressing a critical gap.
• New regimens for visceral leishmaniasis and malaria adaptations.

These innovations have saved millions of lives, demonstrating a patient-needs-driven model that bypasses traditional profit motives. DNDi's success in clinical trials and regulatory approvals offers a blueprint for UAE researchers aiming for high-impact publications.

Dubai Health: Pioneering UAE's Academic Health Ecosystem

Dubai Health operates as the emirate's first integrated academic health system, encompassing six hospitals, 26 ambulatory centers, 21 medical fitness facilities, and MBRU. This structure fuses clinical care, education, and research, embodying the 'Patient First' ethos. MBRU, its academic arm, has graduated 170 doctors since 2016 and excels in translational research, such as the first Arab Pangenome Reference identifying novel genetic variants for precision medicine.

With centers like the Center for Genomic Discovery, Dubai Health fosters interdisciplinary R&D. The DNDi partnership amplifies this by infusing global NTD expertise, promising joint publications and enhanced research profiles for UAE faculty and students. Explore research jobs in this dynamic ecosystem.

Core Pillars of the DNDi-Dubai Health Collaboration

The MoU outlines multifaceted cooperation:

• Joint Research Initiatives: Scoping priority projects in drug discovery, clinical trials, regulatory science, and public health policy.
• AI Integration: Applying artificial intelligence to accelerate health research, from diagnostics to data analysis.
• Education and Training: Guest lectures, curriculum co-development, student co-supervision, and exchanges.
• Knowledge Dissemination: Co-hosting conferences, workshops, and collaborative publications.

Focus areas include viral diseases, pandemic preparedness, and fungal infections like mycetoma, directly supporting high-caliber research outputs.

Empowering UAE Higher Education Through Training Programs

A highlight is MBRU students' participation in DNDi-led fieldwork and clinical research in Africa and Asia. This hands-on exposure to patients and the drug development pipeline—from discovery to delivery—equips future researchers with practical skills. Faculty exchanges ensure bidirectional knowledge flow, fostering joint grant applications and peer-reviewed papers.

In UAE's competitive higher ed landscape, such programs elevate research capacity. MBRU's MD program and genomics focus complement DNDi's needs-driven approach, potentially yielding publications in top journals. Aspiring academics can find opportunities via higher ed faculty jobs.

Targeting Key Neglected Diseases with Research Innovation

DNDi's portfolio targets diseases ripe for UAE involvement:

MENA relevance includes leishmaniasis endemicity. Collaborative trials could produce groundbreaking UAE-led studies.

Boosting Research Publications and Global Visibility

As Research Publication News, this partnership heralds a surge in UAE-originated papers on NTDs. Joint authorship on clinical data, AI applications, and epidemiological studies will enhance academic profiles. Dubai Health's genomic prowess pairs with DNDi's field data for novel insights, aligning with UAE's National Genome Strategy.

Stakeholders anticipate increased Scopus-indexed outputs, mirroring MBRU's pangenome milestone. For career advice, visit how to write a winning academic CV.

Challenges and Solutions in NTD Research

Challenges include low commercial interest, diagnostic gaps, and access barriers. The partnership counters these via open-access models, capacity building, and policy advocacy. Step-by-step: 1) Identify priorities, 2) Secure funding, 3) Conduct trials, 4) Publish and disseminate.

• Benefits: Accelerated discoveries, trained workforce.
• Risks: Logistical hurdles in endemic areas—mitigated by DNDi's experience.

Implications for UAE's Higher Education Landscape

This elevates UAE universities like MBRU in global health research rankings. Ties to UAE academic opportunities foster interdisciplinary teams, attracting talent. Broader ecosystem benefits: enhanced research jobs, international collaborations.

Photo by Markus Winkler on Unsplash

Future Outlook and Global Ramifications

Looking ahead, expect pilot projects by 2027, first joint publications soon after. This sets a precedent for Middle East R&D hubs, contributing to WHO NTD roadmap. UAE researchers poised for leadership. Explore research assistant jobs, postdoc positions, and rate my professor for insights. For jobs, check higher ed jobs and university jobs.